Home » Stocks » ARMP

Armata Pharmaceuticals, Inc. (ARMP)

Stock Price: $3.17 USD 0.03 (0.96%)
Updated November 27, 1:00 PM EST - Market closed

Stock Price Chart

Key Info

Market Cap 59.29M
Revenue (ttm) 319,000
Net Income (ttm) -20.14M
Shares Out 18.70M
EPS (ttm) -1.42
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 27
Last Price $3.17
Previous Close $3.14
Change ($) 0.03
Change (%) 0.96%
Day's Open 3.20
Day's Range 3.12 - 3.20
Day's Volume 13,644
52-Week Range 2.52 - 6.92

More Stats

Market Cap 59.29M
Enterprise Value 55.24M
Earnings Date (est) Jan 1, 1970
Ex-Dividend Date n/a
Shares Outstanding 18.70M
Float n/a
EPS (basic) -1.50
EPS (diluted) -1.42
FCF / Share -0.82
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 39,690
Short Ratio 2.82
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 185.85
PB Ratio 2.39
Revenue 319,000
Operating Income -19.51M
Net Income -20.14M
Free Cash Flow -15.08M
Net Cash 4.05M
Net Cash / Share 0.22
Gross Margin 100.00%
Operating Margin -6,115.99%
Profit Margin -6,314.40%
FCF Margin -4,728.21%
ROA -31.42%
ROE -94.23%
ROIC -87.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$7.25*
(128.71% upside)
Low
5.00
Current: $3.17
High
9.00
Target: 7.25
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112008
Revenue--0.120.260.480.410.080.660.128.72
Revenue Growth---55.77%-45.26%16.14%404.94%-87.8%453.33%-98.62%-
Gross Profit--0.120.260.480.410.080.660.128.72
Operating Income-19.75-17.66-16.16-23.38-10.23-14.11-12.38-4.02-3.91-21.17
Net Income-19.48-16.70-12.84-18.84-0.5223.11-64.58-1.11-3.79-20.72
Shares Outstanding7.834.650.460.070.040.030.010.010.01-
Earnings Per Share-2.55-3.59-30.52-345.37-278.59-326.19-4,479.91-140.00-559.99-7,279.85
Operating Cash Flow-15.58-10.63-9.19-10.61-9.78-12.57-6.29-4.28--10.31
Capital Expenditures-0.13-0.81-0.06-0.28-0.21-1.20-0.10-0.05--0.66
Free Cash Flow-15.71-11.44-9.25-10.89-9.99-13.77-6.39-4.33--10.97
Cash & Equivalents6.7310.465.135.719.376.5820.360.861.105.22
Total Debt2.86--0.80---3.652.70-
Net Cash / Debt3.8710.465.134.919.376.5820.36-2.79-1.605.22
Assets25.4514.5511.1418.1531.4928.6241.2122.0711.487.15
Liabilities10.866.853.418.436.8923.1963.139.134.3310.92
Book Value14.597.697.739.7212.713.44-22.6312.947.15-3.77
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Armata Pharmaceuticals, Inc.
Country United States
Employees 33
CEO Todd R. Patrick

Stock Information

Ticker Symbol ARMP
Stock Exchange NYSE American
Sector Healthcare
Industry Biotechnology
Unique Identifier NYSEAMERICAN: ARMP

Description

Armata Pharmaceuticals, a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for the treatment of antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates includes AP-SA02, which is in Phase 1b/2 clinical trial and AP-SA01 that targets staphylococcus aureus, including multidrug-resistant strains. It is also developing and advancing AP-PA02 that is in Phase 1b/2 clinical trial for treating diseases caused by pseudomonas aeruginosa. The company is headquartered in Marina del Rey, California.